---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-001234"
form_type: "8-K"
ticker: "MBOT"
cik: "0000883975"
company_name: "Microbot Medical Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T11:00:01.086872+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Microbot Medical reaffirms 2025 achievements, outlines 2026 milestones including Full Market Release in Q2

## Summary
- Received FDA 510(k) clearance for LIBERTY, first single-use remotely operated robotic system for peripheral endovascular procedures.
- Emory University Hospital became first adopter of LIBERTY under Limited Market Release; 100% robotic navigation success in ACCESS PVI trial.
- Full Market Release of LIBERTY planned for Q2 2026, coinciding with SIR conference.
- Targeting 2.5 million annual peripheral endovascular procedures in U.S.; building pipeline for cardiology and neurovascular spaces.
- Expanded IP portfolio to 20 patents granted, 52 applications pending; balance sheet bolstered with non-dilutive grant.

## SEC filing metadata
- accession: 0001493152-26-001234
- form_type: 8-K
- ticker: MBOT
- cik: 0000883975
- company_name: Microbot Medical Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/883975/000149315226001234/0001493152-26-001234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/883975/000149315226001234/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-001234
- JSON: https://secwatch.observer/filing/0001493152-26-001234.json
- Plain text: https://secwatch.observer/filing/0001493152-26-001234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.